Hospital Acquired Infections Therapeutic Market By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By Infection Type (Urinary Tract Infections, Ventilator-associated Pneumonia, Surgical Site Infections, Bloodstream Infections, Other Hospital Infections): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2026

Published Date: 26-Feb-2021 Category: Medical Device Report Format : PDF Pages: 110 Report Code: ZMR-5837 Status : Published

The Hospital Acquired Infections Therapeutic Market is set for a quick growth over the forecast period. In terms of revenue, the global Hospital Acquired Infections Therapeutic Market accounted for USD 10.3 billion in 2019 and is expected to reach USD 12.5 billion by 2026 at a CAGR of 2.4 % during the forecast period.

Description

The Hospital Acquired Infections Therapeutic Market is set for a quick growth over the forecast period. In terms of revenue, the global Hospital Acquired Infections Therapeutic Market accounted for USD 10.3 billion in 2019 and is expected to reach USD 12.5 billion by 2026 at a CAGR of 2.4 % during the forecast period.

Global Hospital Acquired Infections Therapeutic Market: Overview

Hospital Acquired Infections Therapeutic Market is also known as Healthcare-associated Infections. It is one of the leading causes of death worldwide. It can be acquired in hospital, nursing home, rehabilitation facility, outpatient clinic, etc. Hospital Acquired Infections (HAIs) are caused due to fungal, viral, and bacterial infections. Poor maintenance of hygiene and growing complacency among healthcare workers are the factors leading to HAIs.

Global Hospital Acquired Infections Therapeutic Market: Growth Factors

Increase in number of hospital admitted patients and improved diagnostics capable of differentiating strains of microbes has resulted in increase of Hospital Acquired Infections worldwide. The rising geriatric population, which is more vulnerable to such ailments, is also driving the market growth. The rise in number of pipeline drugs specifically developing for the hospital acquired infections and an increase in R&D investments expected to boost the market growth over the forecast period. Improvement in the healthcare infrastructure is also likely to boost the market of Hospital Acquired Infections Therapeutic globally.

Global Hospital Acquired Infections Therapeutic Market: Segmentation

The Hospital Acquired Infections Therapeutic Market is segmented based on drug class, infection type and region. On the basis of drug class, the Hospital Acquired Infections Therapeutic Market is segmented into Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs. In 2019, the Antibacterial Drugs dominated the market as most of the cases were caused due to bacteria and thus treated with antibacterial drugs. Based on infection type, the Hospital Acquired Infections Therapeutic Market is bifurcated into Urinary Tract Infections, Ventilator-associated Pneumonia, Surgical Site Infections, Bloodstream Infections, Other Hospital Infections. In 2019, the Surgical Site Infections held the maximum number of shares due to the rising number of surgical procedures and cases.

Global Hospital Acquired Infections Therapeutic Market: Regional Analysis

Europe dominated the market for Hospital Acquired Infections due to the high prevalence of HAIs in European countries and increasing approvals and launch of novel HAI therapeutic drugs in the region. Furthermore, higher accessibility of novel hospital-acquired infection therapeutics in the European is further expected to drive the growth of the region.

In Asia Pacific, the market for HAIs therapeutics is anticipated to show significant growth during the forecast period due to factors such as increasing prevalence of chronic diseases in emerging economies such as India and China which has led to increased hospitalizations.

Global Hospital Acquired Infections Therapeutic Market: Competitive Players

Some of key players in Hospital Acquired Infections Therapeutic Market are Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Limited, AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Cubist Pharmaceuticals, Inc., and Allergan Plc. among others. The key players are forming various strategies such as product launches, collaborations, product development to gain competitive advantage in the market.

The global Hospital Acquired Infections Therapeutic Market is segmented as follows:

By Drug Class

  • Antibacterial Drugs
  • Antiviral Drugs
  • Antifungal Drugs

By Infection Type

  • Urinary Tract Infections
  • Ventilator-associated Pneumonia
  • Surgical Site Infections
  • Bloodstream Infections
  • Other Hospital Infection

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1.Preface
    • 1.1.Report Description
    • 1.1.Report Scope
  • Chapter 2.Research Methodulogy
    • 2.1.Research Methodulogy
    • 2.2.Secondary Research
    • 2.3.Primary Research
    • 2.4.Models
      • 2.4.1.Company Share Analysis Model
      • 2.4.2.Revenue Based Modeling
    • 2.5.Research Limitations
  • Chapter 3.Executive Summary
    • 3.1.Global Hospital Acquired Infections Therapeutic Market, 2016 – 2026 (Million)
    • 3.2.Global Hospital Acquired Infections Therapeutic Market: Snapshot
  • Chapter 4.Hospital Acquired Infections Therapeutic Market – Industry Analysis
    • 4.1.Introduction
    • 4.2.Market Drivers
    • 4.3.Market Restraints
    • 4.4.Market Opportunities
    • 4.5.Porter’s Five Forces Analysis
    • 4.6.COVID 19 Impact Analysis
      • 4.6.1.1.Impact on Product Development and Technulogy Adoption
      • 4.6.1.2.Gap Analysis
  • Chapter 5.Investment Proposition Analysis
    • 5.1.Global Hospital Acquired Infections Therapeutic Market Attractiveness, By Drug Class
    • 5.2.Global Hospital Acquired Infections Therapeutic Market Attractiveness, By Infection Type
    • 5.3.Global Hospital Acquired Infections Therapeutic Market Attractiveness, By Region
  • Chapter 6.Competitive Landscape
    • 6.1.Company Market Share Analysis - 2019
      • 6.1.1.Global Hospital Acquired Infections Therapeutic Market: Company Market Share, 2019
    • 6.2.Strategic Developments
    • 7.1.Global Hospital Acquired Infections Therapeutic Market Overview: by Drug Class
      • 7.1.1.Global Hospital Acquired Infections Therapeutic Market Revenue Share, by Drug Class, 2019 & 2026
    • 7.2.Global Hospital Acquired Infections Therapeutic Market Analysis/Overview – By Drug Class
      • 7.2.1.Antibacterial Drugs – Overview/Analysis
      • 7.2.2.Antiviral Drugs – Overview/Analysis
      • 7.2.3.Antifungal Drugs – Overview/Analysis
    • 7.3.Antibacterial Drugs
      • 7.3.1.Global Hospital Acquired Infections Therapeutic Market for Antibacterial Drugs, Revenue (Million) 2016 - 2026
    • 7.4.Antiviral Drugs
      • 7.4.1.Global Hospital Acquired Infections Therapeutic Market for Antiviral Drugs, Revenue (Million) 2016 - 2026
    • 7.5.Antifungal Drugs
      • 7.5.1.Global Hospital Acquired Infections Therapeutic Market for Antifungal Drugs, Revenue (Million) 2016 - 2026
    • 8.1.Global Hospital Acquired Infections Therapeutic Market Overview: by Infection Type
      • 8.1.1.Global Hospital Acquired Infections Therapeutic Market Revenue Share, by Infection Type, 2019 & 2026
    • 8.2.Global Hospital Acquired Infections Therapeutic Market Analysis/Overview – By Infection Type
      • 8.2.1.Urinary Tract Infections – Overview/Analysis
      • 8.2.2.Ventilator-associated Pneumonia – Overview/Analysis
      • 8.2.3.Surgical Site Infections – Overview/Analysis
      • 8.2.4.Bloodstream Infections – Overview/Analysis
      • 8.2.5.Other Hospital Infection – Overview/Analysis
    • 8.3.Urinary Tract Infections
      • 8.3.1.Global Hospital Acquired Infections Therapeutic Market for Urinary Tract Infections, Revenue (Million) 2016 - 2026
    • 8.4.Ventilator-associated Pneumonia
      • 8.4.1.Global Hospital Acquired Infections Therapeutic Market for Ventilator-associated Pneumonia, Revenue (Million) 2016 - 2026
    • 8.5.Surgical Site Infections
      • 8.5.1.Global Hospital Acquired Infections Therapeutic Market for Surgical Site Infections, Revenue (Million) 2016 - 2026
    • 8.6.Bloodstream Infections
      • 8.6.1.Global Hospital Acquired Infections Therapeutic Market for Bloodstream Infections, Revenue (Million) 2016 - 2026
    • 8.7.Other Hospital Infection
      • 8.7.1.Global Hospital Acquired Infections Therapeutic Market for Other Hospital Infection, Revenue (Million) 2016 - 2026
  • Chapter 9.Hospital Acquired Infections Therapeutic Market – Regional Analysis
    • 9.1.Global Hospital Acquired Infections Therapeutic Market: Regional Overview
      • 9.1.1.Global Hospital Acquired Infections Therapeutic Market Revenue Share, by Region, 2019 & 2026
      • 9.1.2.Global Hospital Acquired Infections Therapeutic Market Revenue, by Region, 2016 – 2026 (Million)
    • 9.2.North America
      • 9.2.1.North America Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
      • 9.2.2.North America Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
      • 9.2.3.North America Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
      • 9.2.4.North America Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
      • 9.2.5. U.S.
      • 9.2.6.Canada
    • 9.3.Europe
      • 9.3.1.Europe Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
      • 9.3.2.Europe Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
      • 9.3.3.Europe Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
      • 9.3.4.Europe Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
      • 9.3.5.Germany
      • 9.3.6.France
      • 9.3.7. U.K.
      • 9.3.8.Italy
      • 9.3.9.Spain
      • 9.3.10.Rest of Europe
    • 9.4.Asia Pacific
      • 9.4.1.Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
      • 9.4.2.Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
      • 9.4.3.Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
      • 9.4.4.Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
      • 9.4.5.China
      • 9.4.6.Japan
      • 9.4.7.India
      • 9.4.8.South Korea
      • 9.4.9.South-East Asia
      • 9.4.10.Rest of Asia Pacific
    • 9.5.Latin America
      • 9.5.1.Latin America Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
      • 9.5.2.Latin America Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
      • 9.5.3.Latin America Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
      • 9.5.4.Latin America Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
      • 9.5.5.Brazil
      • 9.5.6.Mexico
      • 9.5.7.Rest of Latin America
    • 9.6.The Middle-East and Africa
      • 9.6.1.The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
      • 9.6.2.The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
      • 9.6.3.The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
      • 9.6.4.The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
      • 9.6.5.GCC Countries
      • 9.6.6.South Africa
      • 9.6.7.Rest of Middle-East Africa
  • Chapter 10.Company Profiles
    • 10.1.Merck & Co., Inc.
      • 10.1.1.Company Overview
      • 10.1.2.Financial Overview
      • 10.1.3.Product Portfulio
      • 10.1.4.Business Strategy
      • 10.1.5.Recent Developments
    • 10.2.Pfizer Inc.
    • 10.3.Bayer AG
    • 10.4.GlaxoSmithKline Plc.
    • 10.5.Daiichi Sankyo Company, Limited
    • 10.6.AbbVie Inc.
    • 10.7.Abbott Laboratories
    • 10.8.F. Hoffmann-La Roche Ltd
    • 10.9.Allergan Plc.
    • 10.1.Cubist Pharmaceuticals, Inc.,

Methodology


Frequently Asked Questions

The Global Hospital Acquired Infections Therapeutic Market was valued at USD 10.3 billion in 2019.

The Global Hospital Acquired Infections Therapeutic Market is expected to reach USD 12.5 billion by 2026 at a CAGR of 2.4 % during the forecast period.

Some of the key factors driving the Global Hospital Acquired Infections Therapeutic Market growth are increase in number of hospital admitted patients , improved diagnostics capable of differentiating strains of microbes, the rising geriatric population, increase in R&D investments, etc.

. Europe dominated the market for Hospital Acquired Infections due to the high prevalence of HAIs in European countries and increasing approvals and launch of novel HAI therapeutic drugs in the region. Furthermore, higher accessibility of novel hospital-acquired infection therapeutics in the European is further expected to drive the growth of the region.

In Asia Pacific, the market for HAIs therapeutics is anticipated to show significant growth during the forecast period.

Some of the major companies operating in the Global Hospital Acquired Infections Therapeutic Market are Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Limited, AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Cubist Pharmaceuticals, Inc., and Allergan Plc. among others.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social